* Xeris Biopharma Holdings Inc reported a quarterly adjusted loss of 10 cents per share for the quarter ended in December, identical to the same quarter last year. The mean expectation of five analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -7 cents per share.
* Revenue rose 33.9% to $44.39 million from a year ago; analysts expected $43.55 million.
* Xeris Biopharma Holdings Inc's reported EPS for the quarter was a loss of 10 cents.
* The company reported a quarterly loss of $13.39 million.
* Xeris Biopharma Holdings Inc shares had risen by 31.1% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 3.9% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $4.50 This summary was machine generated from LSEG data March 6 at 02:40 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.10 -0.10 Met
Sep. 30 2023 -0.12 -0.09 Beat
Jun. 30 2023 -0.13 -0.14 Missed
Mar. 31 2023 -0.17 -0.12 Beat
Comments